Dr. SALHANICK. Yes, that is correct.

Senator NELSON. You have then obviously reviewed the literature of the studies that have been made?

Dr. SALHANICK. We attempted to collect by various mechanisms, including chemical reviews, the various bibliography services in the world, all the literature we could find up to the time of that conference. We distributed these bibliographies to the individuals whom we thought were most expert in the various fields.

Obviously, there is wide range in that kind of selection, and they published, we think, fairly good review articles of each of seven or eight areas in that book.

In addition, we asked individuals who had been doing research currently to present their findings at that conference, and those findings are also included in the book.

Third, we encourage at that time as much discussion as possible hoping that if there were a scientific way of resolving some of our lack of knowledge that it would come out in discussion.

I can only say that after reviewing approximately 18 or 20 tapes of discussion——

Senator NELSON. Eighteen to twenty what?

Dr. SALHANICK (continuing). Tapes of discussion over a period of 4 days, that there was practically no disagreement among the scientists on the data which presented. The interpretations are another matter, but the data presented were generally accepted.

Senator NELSON. Has anybody outlined a protocol to be followed in the kind of investigations and the size and nature of them?

Dr. SALHANICK. To my knowledge, no. I think it may be very difficult to solve some of the problems which we are trying to solve. I cited some of those reasons in my statement. The various types of pills which exist mean that it is difficult to have a controlled study in respect to the type of pill.

The rapidity with which people move from one pill to another, from one city to another, means that a population for study would be difficult to locate and stabilize.

We do not know a lot about dosages. It is hard to follow patients for a long period of time and still keep in mind the primary need of the patient, which is not the research project but her particular medical problems. So that, considering all of the limitations, I think it is very difficult to do the investigation, and I think it will demand great ingenuity on the part of the investigators involved.

Senator NELSON. We have not yet had witnesses from HEW, NIH, FDA—we will have one from FDA later. Are you familiar with any research, ongoing research, by any of the Federal agencies now or any protocols they have developed for research?

Dr. SALHANICK. Yes, sir. I am on the advisory committee of the Population Center of the National Institute of Child Health and Human Development. Dr. Corfman is here, he is the head of it, and they have initiated a program to encourage investigation in the development of new contraceptives, and they have a program to attempt to define the consequences of using pills.

Protocols are developed by investigators, and it is my understanding some protocols are being investigated by the Institute itself.

Senator NELSON. How extensive have been the metabolic studies that we have had thus far?